Advertisement Edgeline and Houston sign development agreement - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Edgeline and Houston sign development agreement

Edgeline Holdings has signed a joint development agreement with Houston Pharmaceuticals to assist the company in obtaining a license for certain patents, several of which are from the University of Mississippi and the University of Louisiana.

Houston Pharmaceuticals will continue collaborations with both universities and assist in securing grants on behalf of the company.

Leonard Ivins, CEO of Edgeline Holdings, said: “Houston Pharmaceuticals will be instrumental in assisting us through the stage of evaluating and licensing these patents and we believe this relationship will add depth to our company, both in name recognition and industry experience.”